ReviewFrontiers in oncology2016
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Review in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics.Diagnostics (Basel, Switzerland) · 2025Review
- Exploring Synergistic Interactions between Natural Compounds and Conventional Chemotherapeutic Drugs in Preclinical Models of Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).Oncogenesis · 2021Article
- Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.Cancer science · 2020Article
- Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN.Cancer medicine · 2020Observational
- Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.PloS one · 2020Article
- Chemotherapy for Lung Cancer in the Era of Personalized Medicine.Tuberculosis and respiratory diseases · 2019Review
- The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma.Tuberculosis and respiratory diseases · 2019Article
- Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.Medical oncology (Northwood, London, England) · 2019Article
- New Frontiers for Molecular Pathology.Frontiers in medicine · 2019Review
- Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.Journal of thoracic disease · 2018Article
- Article
- Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.Tuberculosis and respiratory diseases · 2018Article
- The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.International journal of molecular sciences · 2017Review
- Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.BBA clinical · 2017Article
- Response to Entrectinib in Differentiated Thyroid Cancer With aJCO precision oncology · 2017Article
- Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification.Frontiers in oncology · 2017Review
- Increased miR-21a provides metabolic advantages through suppression of FBP1 expression in non-small cell lung cancer cells.American journal of cancer research · 2017Article
- Upregulation of LncRNA-HIT promotes migration and invasion of non-small cell lung cancer cells by association with ZEB1.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.